Financials Peijia Medical Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:57 2024-06-25 EDT			5-day change	1st Jan Change
2.46 ^HKD	-4.65%		-32.79%	-66.71%

06-23	Peijia Medical Limited commences an Equity Buyback Plan for 67,885,680 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	CI
06-20	Peijia Medical Launches Share Buyback Plan	MT

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	15,022	7,261	5,677	4,536	1,541	-	-
Enterprise Value (EV) ¹	12,573	4,972	4,140	3,961	1,061	1,357	1,541
P/E ratio	-	-12.6 x	-13.8 x	-11.6 x	-7.04 x	-16.3 x	-13.5 x
Yield	-	-	-	-	-	-	-
Capitalization / Revenue	389 x	53.2 x	22.6 x	10.3 x	2.37 x	1.74 x	1.72 x
EV / Revenue	325 x	36.4 x	16.5 x	8.98 x	1.63 x	1.53 x	1.72 x
EV / EBITDA	-32.7 x	-23 x	-8 x	-10.5 x	-5.96 x	-23 x	-
EV / FCF	-60,929,436 x	-9,824,887 x	-7,155,409 x	-4,403,228 x	-	-	-
FCF Yield	-0%	-0%	-0%	-0%	-	-	-
Price to Book	5.33 x	2.39 x	2.15 x	2.01 x	0.75 x	0.79 x	0.82 x
Nbr of stocks (in thousands)	632,918	670,013	672,429	675,331	673,630	-	-
Reference price ²	23.73	10.84	8.443	6.717	2.288	2.288	2.288
Announcement Date	3/29/21	3/31/22	3/31/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	38.66	136.5	250.8	441.1	650.1	887.3	897
EBITDA ¹	-384.2	-215.8	-517.2	-375.8	-177.9	-59.03	-
EBIT ¹	-403.7	-243.3	-562	-434.7	-248.5	-115.2	-124
Operating Margin	-1,044.41%	-178.22%	-224.05%	-98.54%	-38.22%	-12.99%	-13.82%
Earnings before Tax (EBT) ¹	-	-574.2	-398.2	-391.5	-220.1	-92.39	-115
Net income ¹	-	-574.2	-407.8	-392.5	-220.1	-92.39	-115
Net margin	-	-420.57%	-162.58%	-88.98%	-33.85%	-10.41%	-12.82%
EPS ²	-	-0.8600	-0.6100	-0.5800	-0.3250	-0.1400	-0.1700
Free Cash Flow	-206.4	-506.1	-578.5	-899.7	-	-	-
FCF margin	-533.84%	-370.68%	-230.65%	-203.95%	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-
Announcement Date	3/29/21	3/31/22	3/31/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-
Net Cash position ¹	2,449	2,288	1,538	575	480	184	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-206	-506	-579	-900	-	-	-
ROE (net income / shareholders' equity)	-34.9%	-8.9%	-18.2%	-16%	-10.3%	-4.49%	-6%
ROA (Net income/ Total Assets)	-20.9%	-	-15.9%	-13.1%	-8%	-3%	-5%
Assets ¹	-	-	2,568	2,994	2,751	3,080	2,300
Book Value Per Share ²	4.450	4.530	3.920	3.350	3.040	2.910	2.780
Cash Flow per Share	-	-	-0.5600	-0.8600	-	-	-
Capex ¹	25.3	69.7	202	316	105	107	109
Capex / Sales	65.33%	51.08%	80.67%	71.68%	16.15%	12.06%	12.15%
Announcement Date	3/29/21	3/31/22	3/31/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.288 CNY

Average target price

9.924 CNY

Spread / Average Target

+333.83%

	1st Jan change	Capi.
PEIJIA MEDICAL LIMITED	-66.71%	223M
STRYKER CORPORATION	+13.39%	129B
SMITH & NEPHEW PLC	-9.21%	11.02B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-16.57%	7.27B
GLAUKOS CORPORATION	+41.54%	5.64B
INSPIRE MEDICAL SYSTEMS, INC.	-31.48%	4.02B
AXONICS, INC.	+8.95%	3.45B
ENOVIS CORPORATION	-19.67%	2.47B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-16.74%	1.91B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-23.55%	1.71B